Microbial Spectrum and Primary Resistance to Rifampicin in Infectious Complications in Vascular Surgery: Limits to the Use of Rifampicin-Bonded Prosthetic Grafts

Abstract

There are reports that rifampicin-bonded prosthetic grafts might be a suitable alternative to autologous grafts in vascular graft infections and infectious vascular complications. We characterize the spectrum of microbial agents and susceptibility to antibiotic treatment, especially to rifampicin, in these patients. We carried out a retrospective analysis of wound-swaps and blood cultures in 48 patients with infected prosthetic vascular grafts or primary infectious vascular complications. In 15 of 48 patients (31%), the analysis showed that the microbial organism causing the infection was resistant or not susceptible to rifampicin. Rifampicin-bonded prosthetic grafts should be used with caution in acute infectious complications in vascular surgery, because in about 30% of the cases, the initiating microbial organisms are resistant or not susceptible to rifampicin. Without preoperative confirmation of susceptibility to rifampicin, autologous reconstruction should be preferred.

Keywords

rifampicin vascular graft infections autologous reconstruction

Get full access to this article

View all access options for this article.

References

Bandyk DF , Novotney ML , Johnson BL , Back MR , Roth SR Use of rifampicin-soaked gelatin-sealed polyester grafts for in-situ treatment of primary aortic and vascular prosthetic infections. J Surg Res. 2001;95(1):44-49.

Hayes PD , Nasim A. , London NJ , et al. In situ replacement of infected aortic grafts with rifampicin-bonded prostheses: the Leicester experience (1992 to 1998). J Vasc Surg. 1999;30(1):92-98.

Young RM , Cherry KJ Jr , Davis PM , et al. The results of in situ prosthetic replacement for infected aortic grafts. Am J Surg. 1999;178(2):136-40.

Nasim A. , Hayes P. , London N. , Barrie WW , Bell PR , Naylor AR Vascular Surgical Society of Great Britain and Ireland: in situ replacement of infected aortic grafts with rifampicin-bonded prostheses. Br J Surg. 1999;86(5):695.

Naylor AR , Clark S. , London NJ , Sayers RD , Macpherson DS , Barrie WW Treatment of major aortic graft infection: preliminary experience with total graft excision and in situ replacement with a rifampicin bonded prosthesis . Eur J Vasc Endovasc Surg. 1995;9(2):252-256.

Koshiko S. , Sasajima T. , Muraki S. , et al. Limitations in the use of rifampicin-gelatin grafts against virulent organisms. J Vasc Surg. 2002;35(4):779-785.

Vicaretti M. , Hawthorne W. , Ao PY , Fletcher JP Does in situ replacement of a staphylococcal infected vascular graft with a rifampicin impregnated gelatin sealed Dacron graft reduce the incidence of subsequent infection? Int Angiol . 1999;18(3):225-232.

Noel AA , Gloviczki P. , Cherry KJ , et al. Abdominal aortic reconstruction in infected fields: earlx results of the United States Cryopreserved Aortic Allograft Registry. J Vasc Surg. 2002;35(5): 847-852.

Chiesa R. , Astore D. , Frigerio S. , et al. Vascular prosthetic graft infection: epidemiology, bacteriology, pathogenesis and treatment. Acta Chir Belg. 2002;102(4):238-247.

10.

Ratliff DA The prevention and treatment of vascular graft infection. In: Earnshaw JJ , Murie JA , eds. The evidence for vascular surgery. Tfm Publishing Limited, Castle Hill Barns Shrewsbury (UK); 2007:229-241.

11.

Goeau-Brissoniere OA , Fabre D. , Leflon-Guibout V. , et al. Comparison of the resistance to infection of rifampicin-bonded gelatine-sealed and silver/collagen-coated polyester prostheses. J Vasc Surg. 2002;35(6):1260-1263.

12.

O’Connor S. , Andrew P. , Batt M. , Bequemin JP A systematic review and meta-analysis for aortic graft infection. J Vasc Surg. 2006;44(1):38-45.